The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0045|75|9|897-906

ISSN： 0270-4137

Source： THE PROSTATE, Vol.75, Iss.9, 2015-06, pp. : 897-906

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The predictive value of ERG protein expression for development of castration‐resistant prostate cancer in hormone‐naïve advanced prostate cancer treated with primary androgen deprivation therapy

By  

THE PROSTATE, Vol. 75, Iss. 14, 2015-10 ,pp. : 1499-1509

John Wiley & Sons Inc

Access to resources Recommend Favorite

Assessment of long‐term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy

By  

CANCER, Vol. 121, Iss. 22, 2015-11 ,pp. : 4071-4079

John Wiley & Sons Inc

Access to resources Recommend Favorite

Association of ERG and TMPRSS2‐ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels

By  

THE PROSTATE, Vol. 75, Iss. 11, 2015-08 ,pp. : 1216-1226

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer

By  

Urologia Internationalis, Vol. 88, Iss. 1, 2011-12 ,pp. : 25-33

Karger

Access to resources Recommend Favorite

Adverse effects of androgen‐deprivation therapy in prostate cancer and their management

By  

BJU INTERNATIONAL, Vol. 115, Iss. S5, 2015-04 ,pp. : 3-13

John Wiley & Sons Inc

Access to resources Recommend Favorite